Robert D Murray1, Bertil Ekman2,3, Sharif Uddin4, Claudio Marelli5, Marcus Quinkler6, Pierre M J Zelissen7. 1. Department of Endocrinology, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK. 2. Department of Endocrinology, Linköping University, Linköping, Sweden. 3. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 4. Shire, Lexington, MA, USA. 5. Shire, Zug, Switzerland. 6. Endocrinology in Charlottenburg, Berlin, Germany. 7. Department of Internal Medicine and Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
CONTEXT AND OBJECTIVE: Treatment for adrenal insufficiency (AI) remains suboptimal. Despite glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life. This study aimed to describe the spectrum of management of glucocorticoid replacement in patients with AI enrolled in the European Adrenal Insufficiency Registry (EU-AIR). DESIGN, SETTING AND PATIENTS: EU-AIR is a prospective, multinational, multicentre, observational study initiated in August 2012 to monitor the long-term safety of glucocorticoid replacement in routine clinical practice in Germany, the Netherlands, Sweden and the UK (ClinicalTrials.gov identifier: NCT01661387). This analysis included 1166 patients with primary and secondary AI (mean disease duration 16·1 ± 11·6 years) receiving long-term glucocorticoid replacement therapy. MAIN OUTCOME MEASURE: Glucocorticoid type, dose, frequency and treatment regimen were examined. RESULTS: Most patients (87·4%) were receiving hydrocortisone. The most common dose range, taken by 42·2% of patients, was 20 to <25 mg/day; however, 12·6% were receiving doses of ≥30 mg/day. Hydrocortisone was being taken once daily by 5·5%, twice daily by 48·7%, three times daily by 43·6% and four times daily by 2·1%. Patients with primary AI received higher replacement doses than those with secondary AI (23·4 ± 8·9 and 19·6 ± 5·9 mg/day, respectively). Twenty-five different regimens were being used to deliver a daily hydrocortisone dose of 20 mg. CONCLUSIONS: We have shown significant heterogeneity in the type, dose, frequency and timing of glucocorticoid replacement in real-world clinical practice. This reflects dose individualization based on patient symptoms and lifestyle in the absence of data supporting the optimal regimen.
CONTEXT AND OBJECTIVE: Treatment for adrenal insufficiency (AI) remains suboptimal. Despite glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life. This study aimed to describe the spectrum of management of glucocorticoid replacement in patients with AI enrolled in the European Adrenal Insufficiency Registry (EU-AIR). DESIGN, SETTING AND PATIENTS: EU-AIR is a prospective, multinational, multicentre, observational study initiated in August 2012 to monitor the long-term safety of glucocorticoid replacement in routine clinical practice in Germany, the Netherlands, Sweden and the UK (ClinicalTrials.gov identifier: NCT01661387). This analysis included 1166 patients with primary and secondary AI (mean disease duration 16·1 ± 11·6 years) receiving long-term glucocorticoid replacement therapy. MAIN OUTCOME MEASURE: Glucocorticoid type, dose, frequency and treatment regimen were examined. RESULTS: Most patients (87·4%) were receiving hydrocortisone. The most common dose range, taken by 42·2% of patients, was 20 to <25 mg/day; however, 12·6% were receiving doses of ≥30 mg/day. Hydrocortisone was being taken once daily by 5·5%, twice daily by 48·7%, three times daily by 43·6% and four times daily by 2·1%. Patients with primary AI received higher replacement doses than those with secondary AI (23·4 ± 8·9 and 19·6 ± 5·9 mg/day, respectively). Twenty-five different regimens were being used to deliver a daily hydrocortisone dose of 20 mg. CONCLUSIONS: We have shown significant heterogeneity in the type, dose, frequency and timing of glucocorticoid replacement in real-world clinical practice. This reflects dose individualization based on patient symptoms and lifestyle in the absence of data supporting the optimal regimen.
Authors: A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi Journal: J Endocrinol Invest Date: 2019-11-26 Impact factor: 4.256
Authors: Marcus Quinkler; Robert D Murray; Pinggao Zhang; Claudio Marelli; Robert Petermann; Andrea M Isidori; Bertil Ekman Journal: Eur J Endocrinol Date: 2021-05-04 Impact factor: 6.664
Authors: James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson Journal: Clin Pharmacol Ther Date: 2020-11-29 Impact factor: 6.903
Authors: Chiara Graziadio; Valeria Hasenmajer; Mary A Venneri; Daniele Gianfrilli; Andrea M Isidori; Emilia Sbardella Journal: Front Endocrinol (Lausanne) Date: 2018-08-03 Impact factor: 5.555
Authors: Audrey Melvin; Dimitrios Chantzichristos; Catriona J Kyle; Scott D Mackenzie; Brian R Walker; Gudmundur Johannsson; Roland H Stimson; Stephen O'Rahilly Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 6.134
Authors: Alberto S Tresoldi; Dana Sumilo; Mary Perrins; Konstantinos A Toulis; Alessandro Prete; Narendra Reddy; John A H Wass; Wiebke Arlt; Krishnarajah Nirantharakumar Journal: J Clin Endocrinol Metab Date: 2020-02-01 Impact factor: 5.958
Authors: Rosemary Dineen; Lucy-Ann Behan; Grainne Kelleher; Mark J Hannon; Jennifer J Brady; Bairbre Rogers; Brian G Keevil; William Tormey; Diarmuid Smith; Christopher J Thompson; Malachi J McKenna; Wiebke Arlt; Paul M Stewart; Amar Agha; Mark Sherlock Journal: BMC Endocr Disord Date: 2020-10-10 Impact factor: 2.763